glucose, (beta-d)-isomer has been researched along with Albuminuria in 58 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (3.45) | 29.6817 |
| 2010's | 40 (68.97) | 24.3611 |
| 2020's | 16 (27.59) | 2.80 |
| Authors | Studies |
|---|---|
| Droebner, K; Eitner, F; Goea, L; Grundmann, M; Hartmann, E; Klar, J; Kolkhof, P; Nordlohne, J; Pavkovic, M | 1 |
| Bjornstad, P; Cherney, DZI; Marquard, J; Neubacher, D; Perkins, BA; Rosenstock, J; Soleymanlou, N | 1 |
| Chen, G; Wang, H; Zhang, W; Zhou, J | 1 |
| Hirayama, K; Iwaki, Y; Kobayashi, M; Maruyama, H; Ohgi, K; Shimohata, H; Takayasu, M; Yamashita, M | 1 |
| Benigni, A; Cerullo, D; Conti, S; Corna, D; Locatelli, M; Remuzzi, G; Rottoli, D; Tomasoni, S; Zanchi, C; Zoja, C | 1 |
| Bellante, R; Berra, C; Bolla, A; Chebat, E; Cimino, V; D'Addio, F; Desenzani, P; Fiorina, P; Folli, F; Franzetti, I; Gandolfi, A; Gazzaruso, C; Genovese, S; Ghelardi, R; Girelli, A; Lazzaroni, E; Loretelli, C; Lunati, ME; Manfrini, R; Montefusco, L; Morpurgo, PS; Muratori, F; Muratori, M; Nasr, MB; Orsi, E; Pastore, I; Plebani, L; Rossi, A; Scaranna, C; Tinari, C; Vallone, L | 1 |
| Aoki, K; Azushima, K; Hanaoka, M; Haruhara, K; Hosokawa, S; Inazumi, K; Ito, Y; Iwamoto, T; Kinguchi, S; Kobayashi, R; Kobayashi, Y; Kondo, Y; Misumi, T; Ohki, K; Ono, S; Orime, K; Osada, U; Sasaki, H; Shibasaki-Kurita, T; Tamura, K; Terauchi, Y; Wakui, H; Yamada, T; Yamakawa, T; Yamanaka, T; Yasuda, G; Yoshii, T; Yutoh, J | 1 |
| Diaz, LJ; Eickhoff, MK; Faber, J; Frimodt-Møller, M; Jensen, MT; Olsen, FJ; Persson, F; Rossing, P | 1 |
| Bakris, GL; Sternlicht, HK | 1 |
| George, JT; Hantel, S; Koitka-Weber, A; Levin, A; Perkovic, V; von Eynatten, M; Wanner, C; Wheeler, DC | 1 |
| Doumas, M; Imprialos, K; Papadopoulos, C; Patoulias, D; Stavropoulos, K | 1 |
| Cauchon, M; Lanthier, L; Masse, M; Plourde, MÉ | 1 |
| Azushima, K; Haruhara, K; Ito, Y; Iwamoto, T; Kinguchi, S; Kobayashi, Y; Kondo, Y; Misumi, T; Osada, U; Tamura, K; Terauchi, Y; Wakui, H; Yamakawa, T; Yamanaka, T; Yasuda, G; Yoshii, T; Yutoh, J | 1 |
| Bhatt, DL; Cahn, A; Dwyer, JP; Gause-Nilsson, I; Goodrich, EL; Heerspink, HHJL; Im, K; Langkilde, AM; Leiter, LA; McGuire, DK; Mosenzon, O; Raz, I; Sabatine, MS; Wilding, JPH; Wiviott, SD; Zelniker, TA | 1 |
| Dabal, TD; Jackson, CD; Patrick, SA | 1 |
| Beddhu, S; Fouque, D; Kalantar-Zadeh, K; Kovesdy, CP; Kramer, HJ | 1 |
| Palau, V; Riera, M; Soler, MJ | 1 |
| Cherney, DZI; Inzucchi, SE; Koitka-Weber, A; Mattheus, M; von Eynatten, M; Wanner, C; Zinman, B | 1 |
| Bayarsengee, U; Cheng, CW; Chiang, YH; Lin, EY; Wang, CC | 1 |
| Chen, S; Duan, H; Hou, B; Li, F; Shi, Y; Wei, J; Wu, H; Zhang, H; Zhao, L | 1 |
| Cain, V; Dekkers, CCJ; Heerspink, HJL; Sjöström, CD; Stefansson, BV; Wheeler, DC | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Cherney, DZ; Dekkers, CCJ; Gansevoort, RT; Heerspink, HJL; Laverman, GD; Petrykiv, S | 1 |
| Anzai, T; Asakura, M; Hamasaki, T; Hashimura, K; Imazu, M; Ito, S; Kitakaze, M; Mori, K; Watanabe, M; Yamamoto, H; Yasuda, S; Yasumura, Y; Yoshihara, F | 1 |
| Aroor, AR; Carpenter, AJ; Chandrasekar, B; Das, NA; DeMarco, VG; Duta, C; Habibi, J; Hayden, MR; Jia, G; Manrique-Acevedo, CM; Martinez-Lemus, L; Mayoux, E; Nistala, R; Padilla, J; Ramirez-Perez, FI | 1 |
| Hantel, S; Kadowaki, T; Koitka-Weber, A; Nangaku, M; Okamura, T; von Eynatten, M; Wanner, C | 1 |
| Cain, VA; Hallow, MK; Heerspink, HJL; Inzucchi, SE; Rossing, P; Sartipy, P; Sjöström, CD; Stefansson, BV | 1 |
| Mallamaci, F; Zoccali, C | 1 |
| Endo, J; Inoue, K; Katsumata, Y; Sano, M; Shirakawa, K; Yano, W | 1 |
| Tuttle, KR | 1 |
| Heerspink, HJL; Idzerda, NMA; Pena, MJ; Sjostrom, DC; Stefansson, BV; Wheeler, DC | 1 |
| Brueckmann, M; Butler, J; Cheung, AK; Fitchett, D; George, J; Koitka-Weber, A; von Eynatten, M; Wanner, C; Zannad, F; Zinman, B; Zwiener, I | 1 |
| Darshi, M; Heerspink, HJL; Kim, JJ; Laverman, GD; Mulder, S; Pena, MJ; Sharma, K | 1 |
| Fukazawa, M; Fukuzawa, T; Honda, K; Kawabe, Y; Mori, T; Nagata, T; Nihei, T; Suzuki, Y; Takeda, M | 1 |
| Gerasimova, M; Koepsell, H; Masuda, T; Mayoux, E; Rieg, T; Rose, MA; Satriano, J; Thomson, SC; Vallon, V | 1 |
| Hayashizaki, Y; Imamura, M; Kihara, R; Kobayashi, Y; Kurosaki, E; Li, Q; Noda, A; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Yamajuku, D; Yokono, M | 1 |
| Bartaun, C; Gembardt, F; Hohenstein, B; Hugo, C; Jarzebska, N; Mayoux, E; Todorov, VT | 1 |
| Gangadharan Komala, M; Gross, S; Huang, C; Mather, A; Mudaliar, H; Panchapakesan, U; Pegg, K; Pollock, CA; Shen, S | 1 |
| Edenhofer, I; Kapoor, S; Mitchell, K; Riwanto, M; Rodriguez, D; Segerer, S; Wüthrich, RP | 1 |
| Bai, X; Bian, F; Chi, J; Jin, S; Li, W; Wang, J; Wu, D; Wu, G; Xing, S; Xu, G; Yang, X; Zheng, T | 1 |
| Edenhofer, I; Kapoor, S; Kipar, A; Mei, C; Riwanto, M; Rodriguez, D; Segerer, S; Wüthrich, RP; Yang, M | 1 |
| Weir, MR | 1 |
| Cain, VA; Gause-Nilsson, I; Heerspink, HJ; Johnsson, E; Sjöström, CD | 1 |
| Borg, DJ; Flemming, NB; Forbes, JM; Fotheringham, AK; Gallo, LA; Harvie, BM; Kinneally, TL; Koepsell, H; McCarthy, DA; Panchapakesan, U; Pollock, C; Vallon, V; Ward, MS; Yeh, SM; Zhuang, A | 1 |
| Broedl, UC; Fitchett, D; Inzucchi, SE; Johansen, OE; Lachin, JM; Mattheus, M; von Eynatten, M; Wanner, C; Woerle, HJ; Zinman, B | 1 |
| Cain, VA; Fioretto, P; Johnsson, E; Sjöström, CD; Stefansson, BV | 1 |
| Cherney, D; Cooper, ME; Groop, PH; Kaspers, S; Lund, SS; Perkins, BA; Pfarr, E; von Eynatten, M; Woerle, HJ | 1 |
| Qi, X; Wang, K; Wu, Y; Zhu, Q | 1 |
| Ishibashi, Y; Matsui, T; Yamagishi, SI | 1 |
| Busetto, L; Fioretto, P; Rossato, M; Vettor, R; Zambon, A | 1 |
| Chen, BB; Chen, GT; Song, Y; Yang, M; Zhang, W; Zhang, Y | 1 |
| Kramer, MHH; Muskiet, MHA; Nieuwdorp, M; Tonneijck, L; van Bommel, EJM; van Raalte, DH | 1 |
| de Zeeuw, D; Heerspink, HJL; Laverman, GD; Petrykiv, SI | 1 |
| Qi, XM; Shen, JJ; Su, J; Wu, YG; Zhang, JJ; Zhang, P | 1 |
| Qi, XM; Su, J; Wang, K; Wu, YG; Zhang, JJ; Zhang, P | 1 |
| Deng, JJ; Liu, DL; Liu, RB; Ma, ST; Niu, R | 1 |
| Chen, YP; Wang, HY | 1 |
| Adachi, T; Iwakura, I; Kitamura, K; Okamoto, Y; Oku, A; Saito, A; Seino, Y; Shihara, N; Tsuda, K; Ueta, K; Yamada, Y; Yano, H; Yasuda, K | 1 |
5 review(s) available for glucose, (beta-d)-isomer and Albuminuria
| Article | Year |
|---|---|
Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Hospitalization; Humans; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Nonproteinuric progressive diabetic kidney disease.
Topics: Albuminuria; Benzhydryl Compounds; Diabetic Nephropathies; Disease Progression; Glucosides; Humans; Proteomics; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.
Topics: Albuminuria; Benzhydryl Compounds; Canagliflozin; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Glucosides; Humans; Hypoglycemic Agents; Lipid Metabolism; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2017 |
15 trial(s) available for glucose, (beta-d)-isomer and Albuminuria
| Article | Year |
|---|---|
Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes st
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Japan; Kidney; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2019 |
Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria - A double blind randomized placebo-controlled crossover trial.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2020 |
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
Topics: Adams-Stokes Syndrome; Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Genital Diseases, Female; Genital Diseases, Male; Glomerular Filtration Rate; Glucosides; Heart Failure; Hospitalization; Humans; Infections; Male; Middle Aged; Mortality; Myocardial Infarction; Placebos; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Topics: Acute Kidney Injury; Adult; Albuminuria; Anti-Inflammatory Agents, Non-Steroidal; Benzhydryl Compounds; Biomarkers; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Glomerular Filtration Rate; Glucosides; Hepatitis A Virus Cellular Receptor 1; Humans; Inflammation Mediators; Interleukin-6; Kidney Glomerulus; Kidney Tubules; Netherlands; Renal Elimination; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER).
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Heart Failure; Humans; Japan; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2018 |
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
Topics: Albuminuria; Asian People; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Follow-Up Studies; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Prognosis; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Ketone Bodies; Male; Metabolome; Metabolomics; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Male; Middle Aged; Renin-Angiotensin System | 2016 |
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney; Male; Microvessels; Middle Aged; Proportional Hazards Models; Risk Factors | 2016 |
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Renal Insufficiency, Chronic; Treatment Outcome | 2016 |
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Clinical study of total glucosides of paeony for the treatment of diabetic kidney disease in patients with diabetes mellitus.
Topics: Adult; Albuminuria; Antihypertensive Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Glucosides; Humans; Losartan; Male; Middle Aged; Paeonia; Phytotherapy; Plant Extracts; Plant Roots; Prospective Studies; Serum Albumin; Tumor Necrosis Factor-alpha | 2016 |
The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients.
Topics: Adolescent; Adult; Aged; Albuminuria; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Placebos; Reproducibility of Results; Treatment Outcome; Young Adult | 2017 |
[Clinical observation on treatment of diabetic nephropathy with compound fructus arctii mixture].
Topics: Adult; Albuminuria; Astragalus propinquus; Diabetic Nephropathies; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Furans; Glucosides; Humans; Losartan; Male; Middle Aged; Phytotherapy | 2004 |
38 other study(ies) available for glucose, (beta-d)-isomer and Albuminuria
| Article | Year |
|---|---|
Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
Topics: Actins; Adaptor Proteins, Signal Transducing; Albuminuria; Animals; Benzhydryl Compounds; Blood Pressure; Calcium-Binding Proteins; Collagen; Creatinine; Disease Models, Animal; Fibrosis; Gene Expression; Glucosides; Kidney; Kidney Diseases; Lymphocytes; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Monocytes; Myofibroblasts; Naphthyridines; Reperfusion Injury; RNA, Messenger; Serpin E2; Sodium-Glucose Transporter 2 Inhibitors; Ureteral Obstruction | 2021 |
Kidney Effects of Empagliflozin in People with Type 1 Diabetes.
Topics: Albuminuria; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Creatinine; Diabetes Mellitus, Type 1; Glomerular Filtration Rate; Glucosides; Hematocrit; Humans; Serum Albumin; Sodium-Glucose Transporter 2 Inhibitors; Uric Acid | 2021 |
Dapagliflozin Reduces Urinary Albumin Excretion by Downregulating the Expression of cAMP, MAPK, and cGMP-PKG Signaling Pathways Associated Genes.
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Cell Line; Cyclic AMP; Cyclic GMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Down-Regulation; Epithelial Cells; Female; Follow-Up Studies; Glucosides; Humans; Male; MAP Kinase Signaling System; Middle Aged; Renal Elimination; Retrospective Studies; RNA-Seq; Serum Albumin, Human; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2021 |
The effect of sodium-glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Lipocalin-2; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Blood Glucose; Caveolin 1; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Endothelial Cells; Female; Glomerular Basement Membrane; Glucosides; Humans; Male; Mice; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Endothelial Growth Factor A | 2022 |
Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?
Topics: Albuminuria; Benzhydryl Compounds; Cross-Over Studies; Diabetes Mellitus; Double-Blind Method; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
[In patients with moderate chronic kidney disease with albuminuria, including non-diabetic patients, does dapagliflozin provide renal and cardiovascular benefit compared to placebo?]
Topics: Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Glucosides; Humans; Male; Middle Aged; Prospective Studies; Sodium, Dietary | 2021 |
Dapagliflozin Improves the Clinical Outcomes of Patients with Chronic Kidney Disease and Albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glomerular Filtration Rate; Glucosides; Humans; Kidney; Renal Insufficiency, Chronic | 2021 |
Biologically plausible trends suggesting that a low-protein diet may enhance the effect of flozination caused by the sodium-glucose cotransporter-2 inhibitor dapagliflozin on albuminuria.
Topics: Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diet, Protein-Restricted; Glucose; Glucosides; Humans; Sodium; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
The reno-cardiovascular connection in the patient with Diabetes mellitus: What's new?
Topics: Albuminuria; Anti-Inflammatory Agents; Benzhydryl Compounds; Cardiovascular Diseases; Cytokines; Diabetes Complications; Diabetic Angiopathies; Diabetic Nephropathies; Glucosides; Heart; Humans; Hypertension, Renal; Hypoglycemic Agents; Kidney; Oxidative Stress; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System | 2017 |
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
The natural compound 2,3,5,4'-tetrahydroxystilbene-2-O-β-d glucoside protects against adriamycin-induced nephropathy through activating the Nrf2-Keap1 antioxidant pathway.
Topics: Albuminuria; Animals; Antioxidants; Cell Line; Doxorubicin; Female; Glucosides; Heme Oxygenase-1; Hypercholesterolemia; Kelch-Like ECH-Associated Protein 1; Kidney; Lipid Peroxidation; Mice; Mice, Inbred BALB C; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Polygonum; RNA Interference; RNA, Small Interfering; Stilbenes | 2018 |
Anthocyanins inhibit high glucose-induced renal tubular cell apoptosis caused by oxidative stress in db/db mice.
Topics: Albuminuria; Animals; Anthocyanins; Apoptosis; bcl-2-Associated X Protein; Blood Glucose; Body Weight; Carrier Proteins; Cell Line; Creatinine; Diabetes Mellitus, Experimental; Fasting; Glucose; Glucosides; Grape Seed Extract; Humans; Kidney Tubules; Male; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Mice, Inbred C57BL; Oxidative Stress; Phosphorylation; Proanthocyanidins; Reactive Oxygen Species; Thioredoxins; Triglycerides; Urea | 2018 |
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Blood Pressure; Body Weight; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2018 |
Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Disease Models, Animal; Endothelium, Vascular; Female; Glucosides; Glycosuria; GPI-Linked Proteins; Humans; Kidney; Mice, Inbred C57BL; Mice, Mutant Strains; Pulsatile Flow; Renal Circulation; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Vascular Resistance; Vascular Stiffness; Vasodilation | 2018 |
Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
Topics: Aged; Albumins; Albuminuria; Benzhydryl Compounds; Biomarkers; Clinical Trials, Phase III as Topic; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Down-Regulation; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypertension; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors | 2019 |
Influence of long term administration of tofogliflozin on chronic inflammation of visceral adipose tissue in mice with obesity induced by a high-fat diet.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Cellular Senescence; Diet, High-Fat; Drug Administration Schedule; Glucose Tolerance Test; Glucosides; Inflammation; Intra-Abdominal Fat; Male; Mice; Mice, Inbred C57BL; Obesity; Osteopontin; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2019 |
SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease.
Topics: Adamantane; Albuminuria; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Glucosides; Humans; Incretins; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 | 2019 |
Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
Topics: Aged; Albuminuria; Benzhydryl Compounds; Biomarkers; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2020 |
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
Topics: Adult; Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Female; Glucosides; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Kidney; Losartan; Mice; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2013 |
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Topics: Adipocytes; Albuminuria; Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Blotting, Western; Diabetes Mellitus; Diabetic Nephropathies; Drinking; Eating; Glomerular Filtration Rate; Glucosides; Heart Rate; Hyperglycemia; Inflammation; Kidney; Kidney Glomerulus; Mice; Mice, Inbred Strains; Real-Time Polymerase Chain Reaction; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Topics: Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Fatty Liver; Glomerular Filtration Rate; Glucose Intolerance; Glucosides; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Kidney; Liver; Male; Oxidative Stress; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes | 2014 |
The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Female; Glucosides; Hypertension; Hypertrophy; Hypoglycemic Agents; Kidney; Mice; Mice, Obese; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2014 |
Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Benzimidazoles; Benzoates; Blood Glucose; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibronectins; Glucose Transporter Type 1; Glucosides; Hypoglycemic Agents; Kidney Tubules, Proximal; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Telmisartan; Toll-Like Receptor 2; Transforming Growth Factor beta1 | 2014 |
Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Biopsy; Body Weight; Cell Proliferation; Cyclic AMP; Disease Models, Animal; Disease Progression; Diuresis; Electrolytes; Epithelial Cells; Glucosides; Kidney; Kidney Function Tests; Male; Polycystic Kidney Diseases; Rats; Sodium-Glucose Transport Proteins; Ultrasonography | 2015 |
A novel mechanism of action for salidroside to alleviate diabetic albuminuria: effects on albumin transcytosis across glomerular endothelial cells.
Topics: Albumins; Albuminuria; AMP-Activated Protein Kinases; Animals; Caveolin 1; Creatinine; Diabetic Nephropathies; Endothelial Cells; Glucose; Glucosides; In Vitro Techniques; Kidney Glomerulus; Mesangial Cells; Mice; Phenols; Phosphorylation; src-Family Kinases; Transcytosis | 2016 |
Inhibition of Sodium-Glucose Cotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Blood Urea Nitrogen; Diuresis; Female; Glucosides; Glycosuria; Kidney; Kidney Function Tests; Male; Organ Size; Polycystic Kidney Diseases; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Urodynamics | 2015 |
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.
Topics: Albuminuria; Animals; Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Administration Schedule; Glucosides; Hepatitis A Virus Cellular Receptor 1; Hypoglycemic Agents; Lipocalin-2; Male; Mice; Treatment Outcome | 2016 |
Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals.
Topics: Acetylglucosaminidase; Albuminuria; Animals; Benzhydryl Compounds; Biomarkers; Blood Glucose; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glucosides; Hypoglycemic Agents; Kidney; Male; Mice, Inbred C57BL; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
SGLT2 Inhibitors and the Diabetic Kidney.
Topics: Albuminuria; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Kidney; Kidney Failure, Chronic; Kidney Glomerulus; Renin-Angiotensin System; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
2,3,5,4'-Tetrahydroxystilbene-2-O-β-d-glucoside exerted protective effects on diabetic nephropathy in mice with hyperglycemia induced by streptozotocin.
Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression Regulation; Glucosides; Kidney; Male; Mice; Mice, Inbred C57BL; RNA, Messenger; Stilbenes | 2016 |
Effects of total glucosides of paeony on oxidative stress in the kidney from diabetic rats.
Topics: Albuminuria; Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Glucosides; Kidney; Male; Malondialdehyde; NF-kappa B; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Paeonia; Phytotherapy; Rats; Rats, Wistar | 2010 |
Total glucosides of paeony regulates JAK2/STAT3 activation and macrophage proliferation in diabetic rat kidneys.
Topics: Albuminuria; Animals; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucosides; Janus Kinase 2; Kidney; Macrophages; Male; Paeonia; Phytotherapy; Plant Extracts; Rats; Rats, Wistar; Signal Transduction; STAT3 Transcription Factor | 2012 |
Effect of arctiin on glomerular filtration barrier damage in STZ-induced diabetic nephropathy rats.
Topics: Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Furans; Gene Expression Regulation; Glomerular Filtration Barrier; Glucosides; Glucuronidase; Intracellular Signaling Peptides and Proteins; Kidney Glomerulus; Male; Membrane Proteins; Metabolome; Rats; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin | 2013 |
T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats.
Topics: Albuminuria; Animals; Blood Glucose; Body Weight; Carbonates; Diabetes Mellitus, Experimental; Glucose Transporter Type 2; Glucosides; Glycated Hemoglobin; Glycosuria; Hyperglycemia; Hypoglycemic Agents; Jejunum; Kidney; Male; Monosaccharide Transport Proteins; Organ Size; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Urine | 2000 |